Increased fibrillar β-amyloid in response to human C1q injections into hippocampus and cortex of APP+PS1 transgenic mice

Neurochemical Research

Volumn 28, Issue 1, 2003, Pages 83-93

  Boyett, Kristal W ^a   DiCarlo, Giovanni ^a   Jantzen, Paul T ^a   Jackson, Jennifer ^a   O'Leary, Charlotte ^a   Wilcock, Donna ^a   Morgan, Dave ^a   Gordon, Marcia N ^a,b  

^a Alzheimer's Research Laboratory   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Alzheimer's disease; Astrocytes; BUB BnJ; Complement; Microglia

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; COMPLEMENT COMPONENT C1Q; CONGO RED; PRESENILIN 1;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CELL ACTIVATION; CONTROLLED STUDY; DISEASE MODEL; HIPPOCAMPUS; MACROGLIA; MICROGLIA; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; TRANSGENIC MOUSE;

AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CEREBRAL CORTEX; COMPLEMENT C1Q; HIPPOCAMPUS; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; PRESENILIN-1;

ANIMALIA; HIPPOCAMPUS HIPPOCAMPUS; MUS MUSCULUS;

EID: 0037267982     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1021600212829     Document Type: Article

References (34)

1. Eikelenboom, P. and Stam, F. C. 1982. Immunoglobulins and complement factors in senile plaques: An immunoperoxidase study. Acta Neuropathol. (Berl). 57:239-242.
2. Webster, S. D., Yang, A. J., Margol, L., Garzon-Rodriguez, W., Glabe, C. G., and Tenner, A. J. 2000. Complement component C1q modulates the phagocytosis of Abeta by microglia. Exp. Neurol. 161:127-138.
3. Webster, S., Bonnell, B., and Rogers, J. 1997. Charge-based binding of complement component C1q to the Alzheimer amyloid beta-peptide. Am. J. Pathol. 150:1531-1536.
4. Rogers, J., Cooper, N. R., Webster, S., Schultz, J., McGeer, P. L., Styren, S. D., Civin, W. H., Brachova, L., Bradt, B., and Ward, P. 1992. Complement activation by beta-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 89:10016-10020.
5. Jiang, H., Burdick, D., Glabe, C. G., Cotman, C. W., and Tenner, A. J. 1994. Beta-amyloid activates complement by binding to a specific region of the collagen-like domain of the C1q A chain. J. Immunol. 152:5050-5059.
6. Watson, M. D., Roher, A. E., Kim, K. S., Spiegel, K., and Emmerling, M. R. 1997. Complement interactions with amyloidbeta1-42: A nidus for inflammation in AD brains. Amyloid: Int. J. Exp. Clin. Invest. 4:147-156.
7. Selkoe, D. J. 2001. Alzheimer's disease: Genes, proteins, and therapy. Physiol. Rev. 81:741-766.
8. Holcomb, L., Gordon, M. N., McGowan, E., Yu, X., Benkovic, S., Jantzen, P., Wright, K., Saad, I., Mueller, R., Morgan, D., Sanders, S., Zehr, C., O'Campo, K., Hardy, J., Prada, C. M., Eckman, C., Younkin, S., Hsiao, K., and Duff, K. 1998. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat. Med. 4:97-100.
9. Gordon, M. N., King, D. L., Diamond, D. M., Jantzen, P. T., Boyett, K. V., Hope, C. E., Hatcher, J. M., DiCarlo, G., Gottschall, W. P., Morgan, D., and Arendash, G. W. 2001. Correlation between cognitive deficits and Abeta deposits in transgenic APP+PS1 mice. Neurobiol. Aging 22:377-385.
10. Matsuoka, Y., Picciano, M., Malester, B., LaFrancois, J., Zehr, C., Daeschner, J. M., Olschowka, J. A., Fonseca, M. I., O'Banion, M. K., Tenner, A. J., Lemere, C. A., and Duff, K. 2001. Inflammatory responses to amyloidosis in a transgenic mouse model of Alzheimer's disease. Am. J. Pathol. 158:1345-1354.
11. Games, D., Adams, D., Alessandrini, R., Barbour, R., Berthelette, P., Blackwell, C., Carr, T., Clemens, J., Donaldson, T., and Gillespie, F. 1995. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 373:523-527.
12. Irizarry, M. C., McNamara, M., Fedorchak, K., Hsiao, K., and Hyman, B. T. 1997. APPSw transgenic mice develop agerelated A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neurophathol. Exp. Neurol. 56:965-973.
13. Irizarry, M. C., Soriano, F., McNamara, M., Page, K. J., Schenk, D., Games, D., and Hyman, B. T. 1997. Abeta deposition is associated with neuropil changes, but not with overt neuronal loss in the human amyloid precursor protein V717F (PDAPP) transgenic mouse. J. Neurosci. 17:7053-7059.
14. Lorenzo, A. and Yankner, B. A. 1994. Beta-amyloid neurotoxicity requires fibril formation and is inhibited by Congo Red. Proc. Natl. Acad. Sci. U.S.A. 91:12243-12247.
15. Howlett, D. R., Jennings, K. H., Lee, D. C., Clark, M. S., Brown, F., Wetzel, R., Wood, S. J., Camilleri, P., and Roberts, G. W. 1995. Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. Neurodegeneration. 4:23-32.
16. Simmons, L. K., May, P. C., Tomaselli, K. J., Rydel, R. E., Fuson, K. S., Brigham, E. F., Wright, S., Lieberburg, I., Becker, G. W., and Brems, D. N. 1994. Secondary structure of amyloid beta peptide correlates with neurotoxic activity in vitro. Mol. Pharmacol. 45:373-379.
17. Mrak, R. E., Sheng, J. G., and Griffin, W. S. 1995. Glial cytokines in Alzheimer's disease: Review and pathogenic implications. Hum. Pathol. 26:816-823.
18. Wright, K. L., Hsiao, K., Duff, K., Morgan, D. G., and Gordon, M. N. 1998. Inflammation in PSAPP Alzheimer's transgenic mice bred into complement sufficient, BUB/BnJ, mouse strain. Soc. Neurosci. Abstr. 24:2430.
19. Ong, G. L., Baker, A. E., and Mattes, M. J. 1992. Analysis of high complement levels in Mus hortulanus and BUB mice. J. Immunol. Methods. 154:37-45.
20. Ong, G. L. and Mattes, M. J. 1989. Mouse strains with typical mammalian levels of complement activity. J. Immunol. Methods. 125:147-158.
21. Webster, S. D., Tenner, A. J., Poulos, T. L., and Cribbs, D. H. 1999. The mouse C1q A-chain sequence alters beta-amyloid-induced complement activation. Neurobiol. Aging. 20:297-304.
22. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274:99-102.
23. Duff, K., Eckman, C., Zehr, C., Yu, X., Prada, C. M., Perez-tur, J., Hutton, M., Buee, L., Harigaya, Y., Yager, D., Morgan, D., Gordon, M. N., Holcomb, L., Refolo, L., Zenk, B., Hardy, J., and Younkin, S. 1996. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 383:710-713.
24. Gordon, M. N., Schreier, W. A., Ou, X., Holcomb, L. A., and Morgan, D. G. 1997. Exaggerated astrocyte reactivity after nigrostriatal deafferentation in the aged rat. J. Comp. Neurol. 388:106-119.
25. Gordon, M. N., Holcomb, L. A., Jantzen, P. T., DiCarlo, G., Wilcock, D., Boyett, K. W., Connor, K., Melachrino, J., O'Callaghan, J. P., and Morgan, D. 2002. Time course of the development of Alzheimer-like pathology in the doubly-transgenic PS1+APP mouse. Exp. Neurol. 173:183-195.
26. Webster, S., Glabe, C., and Rogers, J. 1995. Multivalent binding of complement protein C1Q to the amyloid beta-peptide (A beta) promotes the nucleation phase of A beta aggregation. Biochem. Biophys. Res. Commun. 217:869-875.
27. Webster, S. D., Park, M., Fonseca, M. I., and Tenner, A. J. 2000. Structural and functional evidence for microglial expression of C1qR(P), the C1q receptor that enhances phagocytosis. J. Leukoc. Biol. 67:109-116.
28. Rozovsky, I., Morgan, T. E., Willoughby, D. A., Dugichi-Djordjevich, M. M., Pasinetti, G. M., Johnson, S. A., and Finch, C. E. 1994. Selective expression of clusterin (SGP-2) and complement C1qB and C4 during responses to neurotoxins in vivo and in vitro. Neuroscience 62:741-758.
29. Pasinetti, G. M., Johnson, S. A., Rozovsky, I., Lampert-Etchells, M., Morgan, D. G., Gordon, M. N., Morgan, T. E., Willoughby, D., and Finch, C. E. 1992. Complement C1qB and C4 mRNAs responses to lesioning in rat brain. Exp. Neurol. 118:117-125.
30. Goldsmith, S. K., Wals, P., Rozovsky, I., Morgan, T. E., and Finch, C. E. 1997. Kainic acid and decorticating lesions stimulate the synthesis of C1q protein in adult rat brain. J. Neurochem. 68:2046-2052.
31. Wright, K. L., Morgan, D. G., and Gordon, M. N. 1997. Complement immunoreactivity in murine brain after kainic acid treatment. Soc. Neurosci. Abstr. 23:1503.
32. Ferraro, T. N., Golden, G. T., Smith, G. G., and Berrettini, W. H. 1995. Differential susceptibility to seizures induced by systemic kainic acid treatment in mature DBA/2J and C57BL/6J mice. Epilepsia 36:301-307.
33. Grilli, M., Diodato, E., Lozza, G., Brusa, R., Casarini, M., Uberti, D., Rozmahel, R., Westaway, D., George-Hyslop, P., Memo, M., and Ongini, E. 2000. Presenilin-1 regulates the neuronal threshold to excitotoxicity both physiologically and pathologically. Proc. Natl. Acad. Sci. U.S.A. 97:12822-12827.
34. Weinbauer, G. F., Galhotra, M. M., and Nieschlag, E. 1985. Focal testicular destruction following intratesticular injection of glycerol in rats. Int. J. Androl. 8:365-375.